RIPK2 and lysosomal pathway: Unveiling a new mechanism for lung cancer metastasis
1Department of Oncology, Graduate school, Hebei Medical University, 050011, Shijiazhuang, China.
Background:
This study aims to explore the role of RIPK2 in lung cancer metastasis and its potential mechanisms.
Methods:
The expression levels of RIPK2 in lung cancer patients and cell lines were detected by immunohistochemistry, qRT-PCR, and Western blot. RIPK2 expression was knocked down using siRNA technology, and its effects on the proliferation, migration, and invasion capabilities of lung cancer cells were assessed through CCK-8, EdU, colony formation, and Transwell assays. Furthermore, by overexpressing RIPK2 and LAMP2, the regulatory effect of RIPK2 on the lysosomal pathway and its mechanism of action in lung cancer metastasis were investigated.
Results:
The results showed that the expression of RIPK2 was significantly increased in lung cancer patients and cell lines. Knockdown of RIPK2 significantly inhibited the migration, invasion, and proliferation capabilities of lung cancer cells, while overexpression of RIPK2 promoted these malignant behaviors. Further studies found that RIPK2 promoted lung cancer metastasis by inhibiting LAMP2 expression, thereby suppressing the lysosomal pathway and altering the tumor microenvironment. Additionally, overexpression of LAMP2 could reverse the promotive effects of RIPK2 overexpression on the malignant behaviors of lung cancer cells.
Conclusion:
This study reveals for the first time that RIPK2 promotes lung cancer metastasis by inhibiting LAMP2 expression, thereby suppressing the lysosomal pathway and altering the tumor microenvironment. In the future, targeted therapy against RIPK2 and LAMP2 may become an effective means to inhibit lung cancer metastasis.
Insights
Receptor-interacting protein kinase 2 (RIPK2) promotes lung cancer metastasis by reducing lysosome-associated membrane protein 2 (LAMP2) levels. Targeting RIPK2 and LAMP2 may offer new therapeutic strategies for lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Lung cancer remains a leading cause of cancer-related mortality worldwide.
- Understanding the molecular mechanisms driving lung cancer metastasis is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the role of Receptor-interacting protein kinase 2 (RIPK2) in lung cancer metastasis.
- To elucidate the underlying molecular mechanisms involving the lysosomal pathway.
Main Methods:
- Assessed RIPK2 expression in lung cancer tissues and cell lines using immunohistochemistry, qRT-PCR, and Western blot.
- Utilized siRNA to knock down RIPK2 and various assays (CCK-8, EdU, colony formation, Transwell) to evaluate effects on cell proliferation, migration, and invasion.
- Investigated RIPK2's regulatory effect on the lysosomal pathway and metastasis via gene overexpression studies.
Main Results:
- RIPK2 expression was significantly elevated in lung cancer.
- RIPK2 knockdown inhibited lung cancer cell proliferation, migration, and invasion, while RIPK2 overexpression promoted these behaviors.
- RIPK2 promoted metastasis by inhibiting LAMP2 expression, suppressing the lysosomal pathway, and altering the tumor microenvironment. LAMP2 overexpression reversed RIPK2's pro-metastatic effects.
Conclusions:
- RIPK2 promotes lung cancer metastasis by inhibiting LAMP2 expression and suppressing the lysosomal pathway.
- Targeting RIPK2 and LAMP2 presents a potential therapeutic strategy for inhibiting lung cancer metastasis.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:22PI3K/mTOR/AKT Signaling Pathway
01:35Cancer Cell Migration through Invadopodia